Infutraze (Zinc Chloride, Potassium Iodide, Sodium Selenite, Copper Chloride Dihydrate, Manganese Chloride Tetr)

Infutraze is used in parenteral nutrition to correct trace element deficiencies and support metabolic function in critically ill patients.

• Trace element deficiency in parenteral nutrition: provides essential zinc, iodine, selenium, copper and manganese to correct deficiencies.
• Critical illness or postoperative state: supports enzymatic and metabolic processes during intensive care.
• Long‑term total parenteral nutrition (TPN): maintains trace element balance over prolonged intravenous feeding.
• Malabsorption syndromes requiring intravenous supplementation: supplies trace elements when enteral absorption is inadequate.

• Infutraze delivers a combination of essential trace elements directly into the bloodstream, where each element acts as a cofactor for specific enzymes. Zinc participates in protein synthesis and immune function, iodine is required for thyroid hormone production, selenium supports antioxidant enzymes, copper is vital for oxidative metabolism, and manganese contributes to carbohydrate and lipid metabolism. Together they restore normal enzymatic activity and metabolic pathways in patients receiving parenteral nutrition.

Infutraze may be associated with infusion‑related reactions and systemic trace element imbalances.

Common Side Effects

• Infusion site pain or irritation: mild discomfort at the catheter site.
• Erythema or redness: localized skin reaction.
• Metallic taste: transient sensation during infusion.
• Nausea: mild gastrointestinal upset.
• Headache: occasional mild headache.
• Mild electrolyte shift: temporary changes in serum electrolytes.

Serious or Rare Side Effects

• Anaphylactic reaction: severe hypersensitivity requiring immediate medical attention.
• Copper toxicity: signs include liver dysfunction and neurological symptoms.
• Zinc overload: may cause copper deficiency and gastrointestinal distress.
• Selenium overdose: risk of respiratory distress or cardiac abnormalities.
• Metabolic acidosis: rare but serious acid‑base disturbance.
• Renal dysfunction: worsening kidney function in susceptible patients.

When using Infutraze, clinicians should consider patient‑specific factors and monitor for potential complications.

• Renal impairment: monitor serum trace element levels and adjust infusion rate.
• Hepatic dysfunction: assess liver function tests before and during therapy.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Pediatric patients: dose adjustments may be required based on weight and age.
• Drug compatibility: verify compatibility with other intravenous solutions before mixing.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infutraze can interact with other agents that affect trace element balance or metabolism.

Major Interactions (Avoid)

• Concurrent high‑dose copper supplementation: risk of copper overload.
• High‑dose zinc supplements: competitive absorption may lead to imbalance.

Moderate Interactions (Monitor Closely)

• Thyroid hormone therapy: iodine content may influence thyroid medication dosing.
• Antioxidant vitamins (e.g., vitamin C): may alter selenium status.
• Renal replacement therapy: may remove administered trace elements, requiring dose adjustment.